Drugs / EPI-326
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07462377 | Mar 2026 → Jul 2029 expected | head and neck squamous cell carcinoma, lipodystrophy due to peptidic growth factors deficiency, non-small cell lung carcinoma | EpiBiologics | Recruiting | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2026-04-19 | EpiBiologics | EpiBiologics Doses First Patient with EPI-326 Bispecific Antibody in Global Phase 1 Study for EGFR-Driven Solid Tumors epibiologics.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | EPI-326 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07462377 ↗ |
| Route | Intravenous | “EPI-326 will be administered in the clinic via IV infusion.” NCT07462377 ↗ |